Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 7Unknown 2Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2

Conditions

Breast Neoplasms 11Neoplasm Metastasis 7Neoplasms 5Carcinoma, Renal Cell 3Tuberous Sclerosis 2Triple Negative Breast Neoplasms 2Recurrence 2Prostatic Neoplasms 2Neuroendocrine Tumors 2Leukemia, Myeloid, Acute 2Gastrointestinal Neoplasms 2Cholangiocarcinoma 2Carcinoma, Neuroendocrine 2Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Sarcoma 1Renal Cell Cancer Metastatic 1Relapsed Pediatric Solid Tumor 1Ovarian Neoplasms 1Osteosarcoma 1Nasopharyngeal Carcinoma 1Metatropic dwarfism 1Melanoma 1Lymphoma 1Liver Neoplasms 1Liver Failure 1Liver Diseases 1Liver Cirrhosis 1Leukemia, Myelomonocytic, Acute 1

Interventions

Cisplatin 3surufatinib 2sintilimab 2lutetium Lu 177 dotatate 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Fluorodeoxyglucose F18 2Everolimus 2toripalimab 1copper dotatate CU-64 1Radiopharmaceuticals 1PE regimen 1Nivolumab 1Interferon-alpha 1IFL protocol 1Gemcitabine 1Fluorouracil 1Etoposide 1EC regimen 1Copper 1Carboplatin 1Capecitabine 1Bevacizumab 164Cu-DOTATATE 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Carcinoma, Neuroendocrine × Everolimus × Clear all
NCT02687958 2023-05-30

Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin

Gruppo Oncologico Italiano di Ricerca Clinica

Phase 2 Unknown
30 enrolled
Endocrine

Carcinoma, Neuroendocrine

NCT02695459 2021-04-20

Cisplatinum and Everolimus in Patients With Metastatic or Unresectable NEC of Extrapulmonary Origin

The Netherlands Cancer Institute

Phase 2 Unknown
39 enrolled
Endocrine

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡